EFM
ALDX icon

E Fund Management’s Aldeyra Therapeutics ALDX Stock Holding History

E Fund Management’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-13,939
Closed -$93K – 308
2023
Q3 		$93K Buy
13,939
+327
+2% +$2.43K 0.01% 285
2023
Q2 		$114K Buy
+13,612
New +$134K 0.01% 298

Other funds holding ALDX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

E Fund Management's ALDX Position: Q4 2023 in Review

E Fund Management sold out of Aldeyra Therapeutics (ALDX) in Q4 2023, closing a stake of 13,939 shares — an estimated $93K sold.

E Fund Management first reported a position in ALDX in Q2 2023 and held it in 2 quarters. The position peaked at $114K in Q2 2023. 105 funds tracked by Wall St. Rank hold ALDX as of Q4 2023.

  • E Fund Management reported no remaining Aldeyra Therapeutics position as of Q4 2023 after selling out during the quarter.
  • E Fund Management sold 13,939 Aldeyra Therapeutics shares in Q4 2023, an estimated $93K.
  • E Fund Management first reported a position in Aldeyra Therapeutics in Q2 2023 and held it in 2 quarters.
  • E Fund Management's Aldeyra Therapeutics position peaked at $114K in Q2 2023.
  • 105 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q4 2023.

Based on E Fund Management's 13F filing for Q4 2023, filed 7 Feb 2024.